OMS 721

Drug Profile

OMS 721

Alternative Names: anti-MASP-2 monoclonal antibody; MASP-2 therapeutic; OMS-721

Latest Information Update: 15 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Omeros Corporation
  • Class Anti-inflammatories; Antithrombotics; Monoclonal antibodies
  • Mechanism of Action MASP2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thrombotic microangiopathies; IgA nephropathy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Haemolytic uraemic syndrome; IgA nephropathy
  • Phase II Glomerulonephritis; Lupus nephritis; Membranous glomerulonephritis; Thrombotic microangiopathies
  • Preclinical Stroke; Wet age-related macular degeneration

Most Recent Events

  • 09 Nov 2017 Efficacy data from a phase II trial in IgA nephropathy released by Omeros
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Haemolytic-uraemic-syndrome(In volunteers) in Netherlands (IV, Injection)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Haemolytic-uraemic-syndrome(In volunteers) in Netherlands (SC, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top